Metabolic Control and Adherence to Therapy in Type 2 Diabetes Mellitus Patients Using IDegLira in a Real-World Setting

Cohen, Cheli Melzer; Chodick, Gabriel; Naftelberg, Shiran; Shehadeh, Naim; Karasik, Avraham

doi:10.1007/s13300-019-00725-9

Cited by 28 publications

(41 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our overall result of a -0.84% reduction in HbA1c, with -1.1% observed in the primary analysis subgroup, is similar to the -0.9% observed overall in a similar real-world study [17] and shows a greater reduction than the -0.65% observed in the Melzer-Cohen et al study conducted in Israel [18]. Furthermore, despite different definitions of the baseline therapy groups, we see a similar pattern of HbA1c reduction in our study and in that of Price et al [17].…”

Section: Discussionsupporting

confidence: 87%

“…The first real-world European study, which included a relatively small sample size of 61 patients from a single Swiss medical center [16], showed a mean reduction in glycated hemoglobin (HbA1c) of -1.7%, which is well within the range of reduction observed in the 26-week DUAL trials (-1.4 to -1.9%) [10][11][12][13][14]. The second European study, which included 611 patients, and the study in Israel, which included 413 patients, reported reductions of -0.9 and -0.65% in HbA1c, respectively [17,18].…”

Section: Introductionsupporting

confidence: 52%

See 1 more Smart Citation

Glycemic Control Among Patients Newly Prescribed IDegLira Across Prior Therapy Group in US Real-World Practice

Egede

Bogdanov²,

Fischer³

et al. 2020

Diabetes Ther

View full text Add to dashboard Cite

Introduction: IDegLira is a fixed-ratio combination of insulin degludec and liraglutide indicated for the treatment of type 2 diabetes (T2D). We report the first real-world study describing change in glycated hemoglobin (HbA1c) among US patients who initiated IDegLira. The aim of the study was to observe and describe changes in glycemic control and weight in patients initiating IDegLira in real-world clinical practice. Methods: Patients in the Practice Fusion electronic medical record database who initiated treatment with IDegLira between March 2017 and June 2018 were identified (n = 1384). To be included in the analyses, the study population needed to meet age, time in database pre-and post-initiation, and availability of HbA1c data at baseline and follow-up requirements. Data were analyzed according to baseline therapy subgroups and whether patients were intensifying (primary analysis group) or simplifying (secondary analysis group) their diabetes treatment. Changes in clinical outcomes from baseline were evaluated by paired t tests and linear regression. Results: The overall study population comprised 296 patients, of whom 206 were included in the primary analysis group and 90 were included in the secondary analysis group. In the adjusted analyses, there was a reduction in HbA1c of-1.1% in the primary analysis group, with the HbA1c reduction in all prior therapy groups ranging from-0.8% for those previously on basal insulin to-1.0% for those previously on non-injectable therapy (p \ 0.0001 for all). In a similar adjusted analysis, there was a statistically significant but small (1.0 lb/0.45 kg) change in weight in the primary analysis group. In the secondary analysis, patients previously on more than one injection daily switched to a more simplified therapy without compromising on glycemic control (HbA1c change of-0.16%). Conclusion: Consistent with previous realworld studies, IDegLira lowered HbA1c across different background prior glucose-lowering therapies, with minimal impact on weight.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Introductionsupporting

confidence: 52%

Glycemic Control Among Patients Newly Prescribed IDegLira Across Prior Therapy Group in US Real-World Practice

Egede

Bogdanov²,

Fischer³

et al. 2020

Diabetes Ther

View full text Add to dashboard Cite

show abstract

“…The advantages of the fixed-dose combination come from the synergy of the separate mechanisms of action of BI and GLP-1RA, resulting in improved glycaemic control compared with its mono-components given separately, thereby also improving patient compliance. An observational real-life data study reported that patients previously treated with a loose-dose combination of BI and GLP-1RA who switched to a fixed-dose combination showed increased adherence with a subsequent improvement in glycaemic control [ 50 ].…”

Section: Discussionmentioning

confidence: 99%

Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies

Fadini

Disoteo²,

Candido

et al. 2021

Diabetes Ther

View full text Add to dashboard Cite

show abstract

“…The method is a once-daily regimen, and it usually has less weight gain or hypoglycemia associated with increased insulin regimens. In addition, Xultophy shows the benefit of reduced gastrointestinal (GI) side effects in comparison with those of GLP-1 RA alone [17,18].…”

Section: Methodsmentioning

confidence: 99%

The Administration of Xultophy for Diabetic Patients on Hemodialysis

Fujikawa

Kato

Bando

et al. 2020

Diab Res Open Access

View full text Add to dashboard Cite

Background: Recent diabetic treatments include Insulin Degludec/ liraglutide (IDeg/Lira, Xultophy) in clinical practice. Authors have continued clinical research concerning diabetes, chronic renal failure, dialysis, and others. Subjects and Methods: Ten patients with type 2 diabetes mellitus (T2DM) undergoing hemodialysis were investigated. They showed that ages 74.5 ± 5.9 years, M/F=6/4, BMI 21.1± 3.8kg/m2, hemodialysis duration 8.1 ± 5.7 years. At the beginning, fundamental data were Cre 8.2 ± 1.9 mg/dL, HbA1c 6.5 ± 0.8%. Xultophy was started on 5-12 doses and continued for 6 months with the same or 1-4 increased doses for better glycemic variability. Results: Out of 10 subjects, the changes in HbA1c showed a decrease in 7, stable in 2, and an increase in 1. HbA1c value was 6.2 ± 0.8% in average at 6 months. There were no remarkable adverse effects by Xultophy for 6 months. Discussion and Conclusion: Xultophy was started at 5-12 doses, which were remarkably lower doses than usual doses with satisfactory efficacy. One of the reasons may be from the characteristic of the patients, who were diabetic with undergoing hemodialysis. Another factor is possibly from liraglutide, which has hepatic clearance with potential vascular protective effects. These results are expected to become reference data for future research.

show abstract

Metabolic Control and Adherence to Therapy in Type 2 Diabetes Mellitus Patients Using IDegLira in a Real-World Setting

Cited by 28 publications

References 21 publications

Glycemic Control Among Patients Newly Prescribed IDegLira Across Prior Therapy Group in US Real-World Practice

Glycemic Control Among Patients Newly Prescribed IDegLira Across Prior Therapy Group in US Real-World Practice

Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies

The Administration of Xultophy for Diabetic Patients on Hemodialysis

Contact Info

Product

Resources

About